News from jazz pharmaceuticals plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 04, 2020, 17:45 ET Jazz Pharmaceuticals Announces Second Quarter 2020 Financial Results

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2020 and updated its 2020 financial guidance. "I...


Jul 22, 2020, 07:30 ET Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium,...


Jul 21, 2020, 16:05 ET Jazz Pharmaceuticals to Report 2020 Second Quarter Financial Results on August 4, 2020

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 second quarter financial results on Tuesday, August 4, 2020,...


Jul 13, 2020, 08:00 ET National Comprehensive Cancer Network® adds Zepzelca™ (lurbinectedin) to Clinical Practice Guidelines in Oncology

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Zepzelca™ (lurbinectedin) was added by the National Comprehensive Cancer Network (NCCN®) ...


Jun 15, 2020, 15:35 ET Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca™ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced along with its partner PharmaMar (MSE: PHM) that the U.S. Food and Drug Administration (FDA)...


Jun 09, 2020, 07:00 ET Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 2.000% Exchangeable Senior Notes due 2026

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced the pricing of $850 million aggregate principal amount of 2.000%...


Jun 08, 2020, 07:00 ET Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2026

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to...


May 27, 2020, 16:05 ET Jazz Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor...


May 14, 2020, 09:53 ET Jazz Pharmaceuticals to Showcase New Data From its Growing Oncology Portfolio at Virtual ASCO and EHA 2020 Meetings

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it and its partners will present seven new abstracts at the virtual American Society of...


May 11, 2020, 08:30 ET Jazz Pharmaceuticals Announces Appointment Of Kim Sablich As Executive Vice President, General Manager Of North America

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Kim Sablich as executive vice president, general manager of North America, ...


May 06, 2020, 16:05 ET Jazz Pharmaceuticals Announces Participation at Upcoming Virtual Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor...


May 05, 2020, 16:05 ET Jazz Pharmaceuticals Announces First Quarter 2020 Financial Results

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2020 and updated 2020 financial guidance. "During...


Apr 29, 2020, 16:05 ET Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that enrollment in the Phase 3 clinical study of defibrotide for the prevention of hepatic...


Apr 21, 2020, 16:05 ET Jazz Pharmaceuticals to Report 2020 First Quarter Financial Results on May 5, 2020

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 first quarter financial results on Tuesday, May 5, 2020, after...


Mar 31, 2020, 16:01 ET Jazz Pharmaceuticals Provides COVID-19 Business Update

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today provided an update regarding the impact of COVID-19 on its business and the actions it is taking to...


Mar 25, 2020, 16:05 ET Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the ...


Feb 26, 2020, 16:05 ET Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following investor...


Feb 25, 2020, 16:05 ET Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2019 Financial Results

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter of 2019 and provided financial...


Feb 17, 2020, 02:30 ET PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer

PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the U.S. Food and Drug Administration (FDA) accepted for filing with...


Feb 11, 2020, 16:05 ET Jazz Pharmaceuticals to Report 2019 Fourth Quarter and Full Year Financial Results on February 25, 2020

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 fourth quarter and full year financial results on Tuesday,...


Jan 22, 2020, 08:00 ET Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on...


Jan 22, 2020, 02:30 ET PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period

PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the waiting period under the Hart-Scott-Rodino Antitrust Improvements...


Jan 20, 2020, 10:35 ET Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission approved Sunosi® (solriamfetol) to improve wakefulness and...


Jan 06, 2020, 16:05 ET Jazz Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 38th Annual J.P. Morgan ...


Dec 30, 2019, 08:00 ET Jazz Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 2/3 Study Evaluating JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in the pivotal Phase 2/3 clinical study for JZP-458, ...